논문 검색

[BACKGROUND] The potential of Lenvatinib to synergize with combined radiotherapy and immunotherapy in LUAD remains incompletely characterized. [METHODS] We investigated Lenvatinib's effects on radiation-induced PD-L1 in LUAD cells and VEGF…

Despite the emerging role of the gut microbiome in colorectal cancer (CRC), its significance in early-onset CRC (EOCRC, …

[BACKGROUND AND PURPOSE] The benefit of adding anti-PD-1 antibodies to definitive chemoradiotherapy (dCRT) in elderly patients with esophageal squamous cell carcinoma (ESCC) remains uncertain. This study evaluated its efficacy and safety ve…

[AIMS] In the phase 3 KEYNOTE-689 trial (NCT03765918) among patients with resectable locally advanced head and neck squamous cell carcinoma (LA HNSCC), perioperative pembrolizumab (pembrolizumab before surgery, then continued with standard-…

[AIMS] Bacillus Calmette-Guérin (BCG)-unresponsive high-risk non-muscle-invasive bladder cancer (HR-NMIBC) with carcinoma (CIS) is aggressive and treatment options are suboptimal. TAR-200, a novel intravesical drug-releasing system, receiv…

[BACKGROUND AND AIM] Bruton tyrosine kinase inhibitors (BTKis) are the standard of care for patients with relapsed/refractory (R/R) chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Ibrutinib and acalabrutinib are two commo…

[BACKGROUND] Bruton tyrosine kinase inhibitors (BTKis) are therapeutic agents for relapsed/refractory chronic lymphocytic leukemia (R/R CLL). Previous indirect treatment comparisons are limited in simultaneously comparing multiple intervent…

[BACKGROUND] Rituximab-pvvr (Ruxience), -abbs (Truxima), and -arrx (Riabni) are biologic therapies approved by the United States Food and Drug Administration (FDA) as biosimilars to originator rituximab (Rituxan). Each is approved for the t…

[BACKGROUND] Ischemic preconditioning of parathyroid glands (IPCP) is biologically plausible but clinical evidence is limited. In this single-center randomized trial (ChiCTR2000039788), we compared IPCP versus control during total thyroidec…

[BACKGROUND] The advantages of postoperative adjuvant chemotherapy (ACT) for gastric cancer patients with pT1N + M0 staging have been a subject of debate. This study aims to assess whether ACT can enhance the overall survival (OS) of postop…

[AIMS] Early detection of hepatocellular carcinoma (HCC) in patients with compensated cirrhosis (CC) is critical for improving prognosis. The GAAD algorithm (gender [biological sex], age, alpha-fetoprotein [AFP], protein induced by vitamin …

[AIM] Inadequate adherence to colorectal cancer screening reduces individual and population level health benefits. Blood-based tests offer a new modality that may help patients overcome barriers, but there are concerns about the impact of p…

[BACKGROUND] Several colorectal cancer (CRC) screening modalities are guideline-recommended in the United States but differ in screening interval and real-world adherence. Accordingly, single-round test performance may not reflect cumulativ…

[AIM] To estimate brain metastases (BM) management costs in Chinese ALK+ advanced non-small-cell lung cancer (NSCLC) patients receiving first-line (1 L) ALK tyrosine kinase inhibitors (TKIs). [METHODS] A survey of 105 clinical experts acro…

[PURPOSE] This study aims to investigate the clinical applicability of omitting chest drainage tube following thoracoscopic sublobar resection. [METHODS] We gathered data from 1,054 patients who met the inclusion criteria and underwent tho…

[CONTEXT] Rabdosin B (RB), an active compound derived from the Chinese herb (Burm. f.) H. Hara, has demonstrated inhibitory effects on non-small cell lung cancer (NSCLC) cell proliferation in prior studies. However, its precise mechanism o…

[AIM] Recent clinical guidelines recommend pembrolizumab plus chemotherapy and cemiplimab plus chemotherapy as key first-line treatment options for metastatic non-small cell lung cancer (mNSCLC). We evaluated the cost-effectiveness of these…

[OBJECTIVE] To investigate the efficacy and adverse reactions of radiotherapy with omitted clinical target volume (CTV) in unresectable stage III non-small cell lung cancer (NSCLC). [METHODS] A total of 423 NSCLC patients admitted to our h…

[BACKGROUND] This study evaluated the cost-effectiveness of Tepotinib versus Capmatinib in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with MET Exon 14 Skipping Mutations in China. [METHODS] An economic evaluati…